Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers
Home › NY › BROOKLYN › ENIGMA MANAGEMENT CORP DBA ALLIANCE LABORATORY

ENIGMA MANAGEMENT CORP DBA ALLIANCE LABORATORY

NPI: 1588757033 · BROOKLYN, NY 11218 · Clinical Medical Laboratory · NPI assigned 10/02/2006

$3.85M
Total Medicaid Paid
211,129
Total Claims
177,133
Beneficiaries
159
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialABRAZI, BELLA (COO)
NPI Enumeration Date10/02/2006

Related Entities

Other providers sharing the same authorized official: ABRAZI, BELLA

ProviderCityStateTotal Paid
UP SERVICES INC BOCA RATON FL $3.94M

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 7,809 $189K
2019 14,459 $480K
2020 21,598 $925K
2021 44,401 $1.11M
2022 66,193 $815K
2023 28,526 $172K
2024 28,143 $163K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 12,898 11,034 $1.25M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 22,720 15,632 $1.13M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 17,554 12,113 $234K
87631 4,471 3,424 $166K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 17,663 12,188 $124K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 4,360 4,186 $75K
80050 General health panel 3,040 2,880 $66K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 2,736 2,250 $59K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 5,337 3,390 $53K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 340 319 $50K
87486 2,593 2,113 $39K
87581 2,595 2,115 $38K
82607 4,553 4,374 $31K
86769 1,307 1,279 $30K
83036 Hemoglobin; glycosylated (A1C) 5,980 5,669 $29K
82746 3,745 3,595 $27K
82728 3,143 2,994 $24K
82784 1,426 1,314 $21K
86317 1,659 1,584 $19K
80061 Lipid panel 6,119 5,780 $19K
84439 4,243 4,059 $19K
84481 4,098 3,859 $18K
84153 1,556 1,475 $18K
84403 1,539 1,440 $16K
86141 2,711 2,553 $15K
86803 2,183 2,049 $14K
83970 734 709 $13K
86328 452 445 $13K
86703 1,058 1,012 $10K
86704 1,523 1,456 $10K
87340 1,446 1,368 $10K
86708 1,490 1,426 $10K
80053 Comprehensive metabolic panel 3,669 3,445 $10K
81000 5,127 4,855 $8K
82785 1,286 1,197 $8K
84165 1,812 1,697 $8K
84550 2,797 2,703 $7K
83090 852 795 $7K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,828 1,697 $6K
86160 548 525 $6K
K1034 Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count 4,529 4,387 $6K
84443 Thyroid stimulating hormone (TSH) 2,152 2,079 $5K
81408 266 111 $5K
81162 269 127 $5K
83001 436 421 $4K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 87 85 $4K
83540 1,870 1,795 $4K
86481 243 224 $4K
86003 236 218 $4K
87481 143 137 $4K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 4,003 3,751 $4K
83550 1,506 1,454 $4K
84270 915 864 $3K
86235 550 526 $3K
84480 2,561 2,364 $3K
84100 1,171 1,125 $3K
86038 902 857 $3K
86735 607 568 $2K
84402 411 393 $2K
83002 294 282 $2K
82977 1,192 1,117 $2K
86480 196 196 $2K
86431 882 855 $2K
83615 825 767 $2K
81226 305 147 $2K
81201 247 98 $2K
85651 1,847 1,760 $2K
86200 502 469 $2K
81405 248 96 $2K
82670 171 171 $2K
86592 858 824 $2K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 84 73 $2K
81406 245 96 $2K
81328 341 171 $2K
86706 788 737 $2K
82043 544 531 $2K
81321 265 110 $1K
81298 249 97 $1K
81404 243 97 $1K
86762 419 385 $1K
83735 908 864 $1K
81225 304 147 $1K
81401 644 267 $1K
81212 266 124 $1K
81317 247 97 $1K
86765 408 373 $1K
82570 571 495 $1K
86695 267 256 $1K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 602 522 $992.79
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 114 106 $928.26
81293 209 59 $908.93
81227 311 147 $867.64
81231 333 166 $867.06
81230 310 145 $867.06
81295 249 97 $840.29
81241 342 173 $822.30
82550 396 367 $810.52
87500 77 74 $747.08
83986 360 324 $696.18
82533 94 94 $682.97
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 98 93 $682.82
86376 159 156 $678.11
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 112 103 $669.21
87653 122 116 $643.28
81291 339 171 $635.08
85730 180 168 $597.80
86787 343 315 $582.27
87086 Culture, bacterial; quantitative colony count, urine 193 190 $537.47
87640 96 89 $530.74
83525 125 122 $496.63
85044 724 682 $494.89
82378 77 77 $492.32
84144 94 94 $482.02
86800 97 96 $432.20
86304 35 33 $421.47
85610 193 181 $406.90
81240 341 172 $402.84
82627 25 25 $344.41
84305 61 61 $343.83
84152 15 15 $340.65
83690 193 185 $339.86
81403 242 97 $333.36
86780 65 64 $327.18
86300 24 22 $325.87
86301 34 32 $313.03
84425 26 26 $279.86
84446 32 32 $268.96
87641 50 47 $259.62
83785 13 13 $255.11
82108 13 13 $243.91
84702 63 60 $220.65
84590 32 32 $220.21
84466 75 74 $219.64
82150 114 112 $212.30
84146 41 41 $212.09
83018 13 13 $195.80
82175 15 15 $189.54
82300 15 15 $184.02
83020 27 27 $175.25
82180 29 29 $163.55
83825 15 15 $162.46
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 85 85 $149.36
84630 29 28 $139.63
84445 12 12 $127.15
82525 15 15 $124.01
83655 15 15 $121.04
84133 46 45 $115.49
86618 15 15 $102.18
84255 15 15 $75.89
84154 55 55 $63.20
84436 12 12 $57.00
82248 123 122 $52.65
84300 18 17 $45.30
80048 Basic metabolic panel (calcium, ionized) 152 150 $21.89
82040 59 58 $9.90
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 25 22 $0.00
84155 29 29 $0.00
81292 38 38 $0.00
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 21 17 $0.00